SAN FRANCISCO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman Outset Medical (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys. The litigation focuses on the propriety of Outset Medical’s disclosures about its business prospects and operations, specifically those concerning its Tablo Hemodialysis System (“Tablo products”). The company received Section 510(k) clearance f ...